571189-65-6

Usage

Uses

4-[6-[(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester is used as an impurity in the development of pharmaceutical drugs, specifically for the treatment of breast cancer.
Used in Pharmaceutical Industry:
4-[6-[(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester is used as an experimental compound for the development of drugs targeting breast cancer. It is an impurity of Palbociclib (P139900), also known as compound number PD-0332991, which is being developed by Pfizer. Palbociclib is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6, playing a crucial role in the regulation of cell cycle progression and has shown potential in treating breast cancer.
In addition to its use in the pharmaceutical industry, 4-[6-[(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester may also have potential applications in other fields, such as materials science or chemical research, due to its unique chemical structure and properties. However, further investigation and research would be required to explore these possibilities.

Upstream product

• 571188-59-5 tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate 
• 1013916-37-4 2-chloro-5-methyl-8-cyclopentylpyridin[2,3-d]pyrimidin-8-hydro-7-one 
• 362656-36-8 8-cyclopentyl-2-methanesulfinyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 39856-50-3 5-bromo2-nitropyridine 
• 571189-16-7 4-(6-nitropyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester 
• 775288-71-6 1-(6-nitropyridin-3-yl)piperazine 

Relevant academic research and scientific papers

DRUG-LIKE MOLECULES AND METHODS FOR THE THERAPEUTIC TARGETING OF VIRAL RNA STRUCTURES

Methods for identifying selective RNA-binding small molecules by NMR screening. The method provides a screening cascade to identify molecules that bind to an RNA structure, such as HIV TAR. Compounds that bind to structured RNAs and that are useful to disrupt the formation of RNA-protein complexes, such as P-TEFb-Tat-TAR complex.

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6

A pharmacological approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small molecule inhibitors has the potential to provide novel cancer therapies for clinical use. Achieving high levels of selectivity for Cdk4/6, versus other ATP-dependent kinases, presents a significant challenge. The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks. It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro. This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concentrations up to 100-fold the IC50 for cell proliferation. On the basis of its selectivity profile and pharmacokinetic profile, compound 43 (PD 0332991) was identified as a drug candidate for the treatment of cancer.